MARKET

BYSI

BYSI

Beyondspring Inc
NASDAQ
1.750
+0.010
+0.58%
After Hours: 1.730 -0.02 -1.15% 16:04 04/13 EDT
OPEN
1.670
PREV CLOSE
1.740
HIGH
1.815
LOW
1.670
VOLUME
2.08K
TURNOVER
--
52 WEEK HIGH
3.440
52 WEEK LOW
1.100
MARKET CAP
71.96M
P/E (TTM)
-70.2851
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BYSI last week (0406-0410)?
Weekly Report · 18h ago
Weekly Report: what happened at BYSI last week (0330-0403)?
Weekly Report · 04/06 10:03
BeyondSpring to present plinabulin-ADC combination data at AACR annual meeting poster session
Reuters · 03/30 11:31
Weekly Report: what happened at BYSI last week (0323-0327)?
Weekly Report · 03/30 10:03
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
Barchart · 03/30 06:30
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted
Reuters · 03/26 13:37
BeyondSpring publishes corporate presentation; plinabulin clinical program advances and SEED targeted protein degradation pipeline grows
Reuters · 03/26 10:21
BeyondSpring FY2025 net loss drops 15% to $14 million; research and development expenses climb 66% to $4 million
Reuters · 03/25 20:37
More
About BYSI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.

Webull offers Beyondspring Inc stock information, including NASDAQ: BYSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BYSI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BYSI stock methods without spending real money on the virtual paper trading platform.